Skip to main content

Fagron delivers topline growth of 21.5% to €173 million

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2022 – 7.00 AM CET

Fagron delivers topline growth of 21.5% to €173 million

Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2022.

Key Highlights

  • Q3 2022 topline growth across all regions
    • Revenue increased by 21.5% to €173 million (10.7% at CER) driven by organic growth, acquisitions, and FX
    • Organic revenue growth of 11.5% for Q3 2022 and 13.5% for 9M 2022 (1.7% and 5.1%, respectively at CER)
  • Robust performance in EMEA and proactive strategic actions in Latin America and North America
    • Continued positive revenue development in EMEA following structured implementation of our strategy
    • Maintaining market leadership in Latin America by streamlining operational approach to counter evolving market dynamics
    • Strong underlying demand in North America affected by global supply chain shortages
    • Inventory management and cost efficiency key focus areas of centralized procurement team to maximize product availability and optimize pricing
  • Continued rollout of disciplined acquisition strategy
    • Integration of Curaphar, Hiperscan, Pharma-pack, and 503B outsourcing facility in Boston facility advances as planned
    • Accelerated integration of Letco
    • Appraising opportunities across all our markets
  • Further progress on environmental and social initiatives
    • Committed to set science-based emission reduction targets as part of sustainability strategy

Rafael Padilla, CEO of Fagron comments

“Our results in the third quarter demonstrate the resilience in our business with positive developments in several markets despite an increasingly challenging macro environment. The performance in EMEA has continued its upwards trajectory following a series of actions aimed at enhancing our competitive edge as well as driving efficiencies. In Latin America, increased competitive pressure and end market softness endure and we remain focused on maintaining market leadership by further optimizing operations and driving commercial efficacy to protect profitability. Finally, in North America, we have further reinforced our focus on quality but have seen impact from various external factors such as a continuation of the syringe shortages and shipment disruptions due to Hurricane Ian.

Given the syringe shortages are likely to linger, we expect our Wichita run rate to remain at current levels through the fourth quarter, despite strong underlying demand, and achieve at least US$95m (annualized) at the end of the period. Combining this with the recently acquired 503B outsourcing facility in Boston, where we have made strong progress by utilizing our commercial expertise at Wichita and have onboarded several new clients, we expect the joint run rate by the end of the year to be above US$110m (annualized).

We remain confident about the prospects of our business globally and reiterate our FY 2022 and mid-term guidance provided earlier in the year“.

Please open the link below for the full press release:
Fagron delivers topline growth of 21.5% to €173 million

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.